Plain-English translation of NCT06791941 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying why some head and neck cancers resist current treatments and come back. By examining tumor tissue from patients—both their original tumor and any recurrent tumor—scientists hope to understand the genetic changes that make cancers harder to treat and develop better treatment strategies in the future.
Many patients with head and neck cancer experience recurrence despite current therapies. Understanding the molecular reasons why tumors become resistant to treatment could unlock new, more effective approaches to prevent this from happening.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will analyze tissue samples from your original tumor and any recurrent tumor to understand genetic changes linked to treatment resistance. Some participants may provide new tissue samples, while others may have their medical records and existing tissue samples reviewed. The study combines laboratory analysis of tumor tissue with detailed follow-up information to identify patterns that could lead to better treatments.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Italy
Sponsor
Regina Elena Cancer Institute
Enrollment target
~18 participants
Started
March 2024
Primary completion
March 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Giovanni Blandino, Doctor
IRCCS National Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.